Skip to Main Content
CWRU Links

2012 Articles

July 2, 2012

Date Released: 2 July 2012
News Banner


Stan Gerson, MD
Director, Case CCC

Cancer Center Retreat 2012: Site Visit orientation and preparation

This year, the Senior Leaders decided the retreat should focus on the scientific and coordination efforts in preparation for the Cancer Center site visit, which will be held October 23 in Thwing Hall on CWRU campus.

The renewal application, all 1560 pages, the effort of over 60 individuals, and supporting the efforts of over 80 individual faculty members of the Cancer Center, has been received by the NCI Cancer Centers Branch. They will be distributing this grant to 24-27 reviewers. Many of these individuals serve as leaders of other cancer centers, are on the parent committee, were present at our last review, or are scientific or shared resource experts in their fields.

The purpose of the site visit is to provide the reviewers and the NCI with a hands-on impression of the coordination efforts undertaken by the cancer center. Of particular interest is our inter-institutional effort, because we are the second largest consortium cancer center in the country (behind Harvard). We will address many issues at the retreat, from scientific content of the program presentations to approaches to showcase interprogrammatic cross disciplinary efforts, clinical research, minorities, and attention to the new guidelines which will impact our review.

The Cancer Center Retreat will be held July 10 from 10 am - 4 pm in Dively. All Senior Leaders, Program Leaders, Shared Resource Directors and managers, cancer center administration, clinical research office, and hospital CTU leaders and directors should plan to attend. If you are not sure whether this retreat is appropriate for you, please contact me directly at

Cancer Genomics

Cancer Center leaders met with the Board of Governors for the Cancer Center on June 20. The major topic of discussion was moving forward with a strategic initiative in cancer genomics across the institutions. From this discussion, a consensus was achieved that prioritizes efforts to develop a robust program across the institutions for evaluating the genomes of cancer patients and their cancers to address the potential for precision evaluation, decision-making, and treatment of cancer. This process will evolve over the next four months as we develop a more focused strategic plan and business plan for implementation of the various aspects of cancer genomics.

Elements include:

  • Increased on-site capacity for high throughput sequencing;
  • Robust and secure databases for genomic storage and analysis;
  • Data sharing agreements that would allow clinical genomics information to be interrogated for discovery research;
  • Clarity of germ line genomics efforts and those focused on tumor abnormalities;
  • Approaches to outsourcing of sequencing needs;
  • Recruitment and training in genomics informatics;
  • Utilization of these resources for diseases outside of cancer;
  • Development of molecular pathology sequencing capacity for diagnostics in a CLIA setting.

The individuals in these discussions welcome your input regarding the next steps that will be taken as the plans mature. Please contact me or one of the following individuals: Drs. Sandy Markowitz, Charis Eng, Lyndsay Harris, Ruth Keri, Brian Bolwell, Jarek Maciejewski, Cliff Harding, Neal Meropol, Rob Dreicer, Jill Barnholtz-Sloan, and Eric Hsi.

Reorganization of the Athymic Animal and Xenograft Facility

The Cancer Center has embarked on an ongoing effort to reorganize the Athymic Animal and Xenograft Core Facility for the benefit of users throughout the center. As these changes evolve, we will keep the membership up to date through the newsletter and revisions to the website.

Leadership: Dr. Daniel Lindner is Director of the facility. He continues to be based at Taussig Cancer Institute (TCI) providing support for human tumor experiments, angiogenesis studies, and pharmacokinetic studies in mice. He will assist members in experimental design and in use of the facility.

Sites: As users appreciate, there are two sites – one at TCI and the other within the Animal Research Core of CWRU. A full listing of services provided by both sites is listed on the core website.

Manager: Kristen Lozada has been named Manager of the Facility at CWRU. This facility will continue to breed and house athymic nude mice (NCRnu/nu), NOD-SCID mice, and other immunodeficient animals, and will develop a suite of services that will be listed on the website within the next week. Kristen has many years of experience with xenograft and animal experimentation, working with Dr. Ruth Keri, who will continue to provide guidance. Please contact Kristen to design experiments at CWRU.

Among services provided are drug administration (IV, IM, IP, SC); blood draw (cardiac, retro-orbital); xenografts, including subcutaneous or orthotopic; transplantation into a variety of organs: mammary fat pad, ovary, oviduct, kidney, and brain (additional sites pending); tail vein and cardiac tumor cell injection, mouse weight and tumor caliper measurements; delivery of mice to imaging core; imaging of uciferase-labeled tumors; organ and tissue harvest; and IACUC protocol consultation.

IACUC protocol approval: All investigators using the facility must have approval from the IACUC to carry out their specific experiments, referencing the IACUC protocol of the facility. The Athymic Animal and Xenograft Core Facility protocol covers the breeding of mice, but your experiment specific information, such as cell lines, numbers of animals, and procedures, whether done in the core facility or in the PI's laboratory, must be listed in your own protocol. Kristen is available to help you to write your protocol.

Mouse colony: The SCID mouse colony is being re-established, and Dr. Keri and Kristen expect that by January 2013 the core will be able to promptly meet investigators' needs for mice. Mice are available during the time up to January, but on a more limited basis. Mice purchased through approved vendors can be housed in the facility.


Cancer Drug Shows Promise in Reversing Alzheimer's Symptoms in ... - Jul 1, 2012
... quite well in mouse models of the disease," said Case Western Reserve neuroscientist and senior author of the study Gary Landreth, PhD.

Mentor High grad's life changes after previously undetected brain ... - Jun 28, 2012
Dr. Lisa Rogers, medical director of neuro-oncology for both University Hospitals and its Seidman Cancer Center, said there's no way of ...

Oncomatrix, National Jewish Health and Case Western Reserve University Join Forces to Attack Invasive Tumors
MarketWatch - Jun 19, 2012
Scientists from National Jewish Health led by Dr. William Schiemann, associate professor, co-director, Breast Cancer Program, now at Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center ...


Reminder: Reporting Clinical Trial Results in

A federal mandate requires reporting of clinical trial results U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of 2007), Title VIII, Section 801, mandates that certain clinical trials have to be registered and results have to be reported in Clinical trial results registration became effective as of September 2008.

The function of clinical trial and result registration is centralized within The Case CCC and April Firstencel, the Case CCC Registration Coordinator, has been working with investigators, study staff and statisticians to ensure that Case CCC complies with federal requirements. This announcement serves as a reminder about our on-going efforts and the need for everybody's assistance and collaboration to meet these obligations. Please direct questions to April Firstencel, Research Coordinator for, Case CCC; 216.286.2294;


American Cancer Society Institutional Research Grant Awards

The Case CCC, with funds from its American Cancer Society Institutional Research Grant (IRG), will provide seed money to foster cancer research by junior faculty who have no current national grant support of their own. Investigators in the Case School of Medicine and Cleveland Clinic Lerner College of Medicine as well as in other schools and colleges in the University are eligible. Grants, not to exceed $30,000 direct costs, will be awarded to investigators who intend to gather preliminary data to be used in seeking future and independently funded programs.

Letter of Intent Deadline: July 9
Application Deadline: August 3

Alex's Lemonade Stand Foundation

Alex's Lemonade Stand Foundation has released a call for applications for the following funding programs:

  • The Bridge Grant is designed for sustaining research projects falling between the end of funding by the NIH R or P Award and the beginning of competitively renewed NIH Award. ALSF will support projects via this mechanism for a maximum of 12 months. Applications will be reviewed on a first come basis and will be accepted until ALSF has funded 3 projects or the respective cycle's due date.
    Deadline: July 16
  • The 'A' Award is a three-year grant designed for young scientists who want to jump-start their career in pediatric oncology research. The ideal candidate has an original project that is not currently being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application.
    Deadline: September 17
  • The Epidemiology Awards are designed to support the research of investigators who have a specific focus on the epidemiology, early detection or the prevention of childhood cancer. ALSF will award support to established investigators who have a track record of peer-reviewed publications in relevant areas. These awards are expected to provide additional funds that will allow investigators to pursue novel and promising epidemiological approaches to understanding the cause of childhood cancers and how such insight can be used for early detection or prevention of childhood cancer.
    Deadline: December 17
Oncology Nursing Society Foundation

The Oncology Nursing Society Foundation is accepting applications for the following opportunities:

  • Research Career Development Awards, funded through an unrestricted grant from Genentech BioOncology, are available for beginning researchers. A beginning researcher is within eight years of completing a terminal degree, or within five years of initiating independent research within a field of inquiry and has not received independent extramural funding in the area of interest.
    Deadline: July 9
  • 2013 Research Grant Funding, supports oncology nursing research. Research projects may include pilot or feasibility studies or the development of a new aspect of a program of research. Funding preference is given to research that addresses the ONS Research Priorities and/or the ONS Research Agenda.
    LOI Deadline: September 1
    Application Deadline: October 1
Robert Wood Johnson Foundation Health & Society Scholars program

The Robert Wood Johnson Foundation Health & Society Scholars program provides two years of support to postdoctoral scholars at all stages of their careers to build the nation's capacity for research and leadership to address the multiple determinants of population health and contribute to policy change.

Deadline: September 21

Case CCC Clinical Trials Protocol Specific Research Support Funding

The Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support funding for Year 2012. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be given a higher priority. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at 216.844.4176 or


June 26, 2012

Featured Article: Many Survivors of Adolescent and Young Adult Cancers Have Chronic Health Problems, Unhealthy Behaviors

Breast Cancers Can Change Biologically as They Progress and Relapse

World Health Organization Classifies Diesel Exhaust a Human Carcinogen

Pre-Existing Mutations May Explain Development of Resistance to Targeted Cancer Drugs

Testing Combination Therapy Could Reveal Clues to Biology of Pancreatic Cancer

In Depth
So Others May Benefit: Young Cancer Patients and Survivors Take Part in Oncofertility Research

A Tough Transition: Cancer Survivorship Plans Slow to Take Hold

Featured Clinical Trial: Trastuzumab for Women with HER2-Low Breast Cancer

Legislative Update Update






**All events are open to anyone interested in attending

July 2

Cancer Imaging Program Meeting canceled

July 3

July 4

Happy Independence Day!

July 5

July 6

Cancer Center Research in Progress will resume in September

Cancer Center Seminar Series will resume in September.

Hematology/Oncology Fellows will resume July 13.

Taussig Cancer Institute Grand Rounds will resume in September

Case CCC Calendar

LRI Calendar


Cancer Center Retreat 2012: Preparation for Site Visit
July 10
10 am - 4 pm
Dively Building

Second Annual Imaging Solutions in Cancer Management: A Case-Based Conference
September 21
Wolstein Research Building
Brochure and Registration Form

National GvHD Health Symposium
November 2
Embassy Suites Cleveland-Rockside


Ninth International Conference of the Society for Integrative Oncology
October 8-10
Albuquerque, NM

Biennial Science of Global Prostate Cancer Disparities conference
November 1-4
Nassau, The Bahamas

Pacific Symposium on Biocomputing 2013
January 3-7, 2013
Fairmont Orchid, Hawaii
Call for Abstracts Deadline: July 31


Mesothelioma Applied Research Foundation
Deadline: July 6

Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research
Deadline Extended: July 9

Case CCC ACS Institutional Research Grant Awards
LOI Deadline: July 9
Application Deadline: August 3

Society of Surgical Oncology Clinical Investigator Award in Breast Cancer Research
Deadline: July 9

ASCO Diagnostic Development Tutorial Attendee Grant
Deadline: July 13

Kinship Foundation Searle Scholars Program
Internal Deadline: July 23
External Deadline: September 28

DOD Prostate Cancer Research Program Health Disparity Research Award
Pre-Application Deadline: July 26
Application Deadline: August 9

Alex's Lemonade Stand Foundation Nursing Grants Program Explorer Awards
Deadline: August 1

Alex's Lemonade Stand Foundation Nursing Grants Program Pathfinder Award: Intermediate Nurse Researcher Grants
Deadline: August 1

Alex's Lemonade Stand Foundation Nursing Grants Program Discovery Award: Independent Nurse Researcher Grants
Deadline: August 1

American Cancer Society Clinical Research Professor
LOI Deadline: August 1
Application Deadline: October 15

International Myeloma Foundation Brian D. Novis Senior Research Award
Deadline: August 1

International Myeloma Foundation Brian D. Novis Junior Research Award
Deadline: August 1

DOD Lung Cancer Research Program Concept Award
Pre-Application Deadline: August 9
Application Deadline: August 23

Uniting Against Lung Cancer (UALC)
Deadline: August 15

University Hospitals Harrington Discovery Institute Scholar-Innovator Grants program
Deadline: August 1

Szent-Györgyi Prize for Progress in Cancer Research
Deadline: September 30

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

Case CCC Protocol Specific Research Support (PSRS)
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

SAIC-Frederick Support of the Cancer Genome Atlas Program
Application Deadline: Open

Solving Kids' Cancer Therapeutic Development Initiative
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

NIH BULLETIN – Notices and Funding Opportunities

Biomarkers for Early Detection of Hematopoietic Malignancies (R21) (PA-12-220)

Biomarkers for Early Detection of Hematopoietic Malignancies (R01) (PA-12-221)

Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) (PAR-11-150)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax


If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to